The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is 18 to 36 months of age
- Participant's current weight and height within the 10th to 90th percentiles
- Parent/caregiver reports that participant consumes milk or a milk-based beverage on a daily basis
- Participant lives at home with parent(s) or other family member(s)
- Signed informed consent and authorization obtained to use and or disclose Protected Health Information (PHI)
Exclusion Criteria:
- Participant who is receiving any breast milk at time of randomization
- Participant with an active infection.
- Participant with a history of underlying disease, chronic disease, or congenital malformation which in the opinion of the Investigator is likely to interfere with the evaluation of the participant.
- Known or suspected intolerance to cow's milk protein
- Participant diagnosed with diabetes
- Participant is from a multiple birth and the sibling(s) are still living
- Participant with a sibling that has participated in this study.
Study Plan
How is the study designed?
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Milk-based beverage w/out DHA
|
|
|
Experimental: Milk-based beverage with DHA
|
|
|
Experimental: Milk-based beverage containing DHA at a higher level
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Blood lipid levels of Docosahexaenoic Acid (DHA) at enrollment and after two months, assessment of usual DHA intake, and product acceptability and use
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Growth
|
|
Adverse Events
|
|
Determination of nutrient status, including iron and vitamin D status
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Susan Carlson, Ph.D., University of Kansas
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 3375-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.